Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on MRNS. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Finally, EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Trading Down 0.6 %

NASDAQ:MRNS opened at $0.32 on Tuesday. The company has a market capitalization of $17.76 million, a P/E ratio of -0.13 and a beta of 1.26. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26. The firm has a fifty day simple moving average of $1.06 and a 200-day simple moving average of $1.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently made changes to their positions in the company. World Investment Advisors LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 3rd quarter valued at about $104,000. Jacobs Levy Equity Management Inc. boosted its position in Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares in the last quarter. Suvretta Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares during the period. GSA Capital Partners LLP increased its position in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after buying an additional 817,050 shares in the last quarter. Finally, abrdn plc increased its position in shares of Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after buying an additional 1,578,329 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.